Trials / Completed
CompletedNCT00314288
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
A Multicenter, Multinational, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Investigate the Anti-dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 360 (planned)
- Sponsor
- EMD Serono · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sarizotan HCl |
Timeline
- Start date
- 2002-07-01
- Completion
- 2003-07-01
- First posted
- 2006-04-13
- Last updated
- 2017-01-23
Locations
51 sites across 11 countries: United States, Belgium, Bulgaria, Canada, France, Germany, Hungary, Portugal, Romania, South Africa, United Kingdom
Source: ClinicalTrials.gov record NCT00314288. Inclusion in this directory is not an endorsement.